Who Paid My Doc
Jay Portnoy
Pediatric Allergy/Immunology Kansas City, MO Medical Doctor
NPI 1568429066 CMS profile 343632
2401 Gillham Rd, Kansas City, MO 64108
General payments
$75,839
Research payments
$3,119
Ownership & investment interest
$0
Research they led as principal investigator
$25,950
Through program year 2025, Jay Portnoy of Kansas City, MO is reported in the CMS Open Payments database as having received $75,839 across 128 general payments and $3,119 in research payments paid to them. Separately, studies naming them as principal investigator received $25,950 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 92nd percentile of Pediatric Allergy/Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $655 | 9 | |
| 2024 | General | $14,464 | 31 | |
| 2023 | General | $10,900 | 23 | |
| 2022 | General | $15,220 | 8 | |
| 2022 | Research | $3,119 | 6 | |
| 2021 | General | $9,104 | 12 | |
| 2020 | General | $4,515 | 6 | |
| 2019 | General | $20,982 | 39 |
Beside peers
- Jay Portnoy
- Pediatric Allergy/Immunology median
- Middle half of Pediatric Allergy/Immunology
- National median
In program year 2025, general payments to Jay Portnoy were reported at $655. Among 289 Pediatric Allergy/Immunology profiles paid that year, the median was $361 and the middle half received between $125 and $2,493.
Show as a table
| Year | Jay Portnoy | Pediatric Allergy/Immunology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $20,982 | $325 | $92–$1,399 | $163 |
| 2020 | $4,515 | $144 | $66–$2,490 | $114 |
| 2021 | $9,104 | $357 | $95–$2,633 | $132 |
| 2022 | $15,220 | $385 | $125–$2,259 | $149 |
| 2023 | $10,900 | $470 | $121–$2,946 | $160 |
| 2024 | $14,464 | $317 | $125–$2,583 | $164 |
| 2025 | $655 | $361 | $125–$2,493 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
134 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Allergy/Immunology in Missouri
Gary Goodman
Pediatric Allergy/Immunology · Saint Louis, MO
Deepika Polineni
Pediatric Allergy/Immunology · Saint Louis, MO
Ray Davis
Pediatric Allergy/Immunology · Saint Louis, MO
William Johnson
Pediatric Allergy/Immunology · Saint Louis, MO
Lisa Suffian
Pediatric Allergy/Immunology · Saint Louis, MO
Mary Jacobson
Pediatric Allergy/Immunology · Kansas City, MO
Related records
Pediatric Allergy/Immunology in Missouri
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Allergy/Immunology
Everyone recorded under this specialty, nationwide.
Doctors in Missouri
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.